Anti–vascular endothelial growth factor (anti-VEGF) injections are typically standard care for eyes with central-involved diabetic macular edema (DME) and vision impairment.
1 Despite the positive effects of anti-VEGF injections on both visual acuity and retinal thickening, DME can persist in some eyes. An exploratory analysis of data from Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol I investigated the frequency of persistent DME through 24 weeks and whether chronic persistent DME had deleterious effects on visual acuity outcomes through 3 years.
2,3 Approximately 40% of eyes receiving monthly ranibizumab had persistent DME through 24 weeks. As these eyes continued treatment, applying a protocol based on changes in visual acuity and optical coherence tomography, the percentage of patients with chronic persistent DME (ie, never resolving at 2 consecutive visits) was 55.8% and 40.1% at the 2-year and 3-year visits, respectively. Visual acuity outcomes appeared slightly less favorable among the eyes in which DME persisted through 3 years; however, visual acuity typically improved from baseline, and substantial (≥ 2-line) loss was uncommon. The DRCR.net retreatment algorithm treats DME to stability (2 consecutive visits without improvement or worsening of vision and central subfield thickness [CST]), not resolution.